Update on prospective markers of treatment response with omalizumab in chronic spontaneous urticaria
Omalizumab
Guideline
Ciclosporin
DOI:
10.26416/aler.7.2.2023.8194
Publication Date:
2023-07-05T07:30:07Z
AUTHORS (4)
ABSTRACT
Chronic spontaneous urticaria (CSU) is the most common form of chronic urticaria, frequently evaluated in allergology and dermatology services, with an increasing incidence, evolution usually several years often incompletely controlled by treatment, strongly impacting patient's quality life. The current therapeutic algorithm recommended international guideline, although useful, not perfect, given fact that it based on a one-size-fits-all approach for all CSU patients: initially, second-generation antihistamines are administered up to maximum dose, case insufficient control, omalizumab added and, last step ciclosporin. Ideally, treatment patients should be individualized predictors response each type avoid less effective options. In recent years, potential clinical laboratory parameters have been described could predict three guideline-recommended lines management CSU. Low level total IgE correlated nonresponse has best evidence omalizumab. Further prospective randomized studies needed confirm and/or identify other response.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....